Singapore, December 31, 2024 – We are thrilled to announce that Professor Patricia LoRusso, D.O., has joined Axcynsis Therapeutics’ Scientific Advisory Board! A globally recognized authority in oncology, Prof. LoRusso brings extensive expertise in clinical research, early-phase drug development, and translational medicine.
Prof. LoRusso has served as Co-Chair of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee and held prominent roles with the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and various NCI peer-review panels. She has authored over 200 peer-reviewed articles and contributed to numerous book chapters.
“As Axcynsis transitions from preclinical to clinical development, we are deeply honored to have Prof. LoRusso join our Scientific Advisory Board,” shared Dr. Zou Bin, CEO of Axcynsis Therapeutics. “Her unparalleled knowledge and strategic guidance will be invaluable as we navigate the complexities of clinical trials and strive to deliver groundbreaking therapies to patients worldwide.”
Currently serving as Associate Director of Experimental Therapeutics at Yale Cancer Center, Prof. LoRusso continues to lead efforts in revolutionizing cancer treatment. Speaking on her new role with Axcynsis, Prof. LoRusso remarked, “I am excited to work with Axcynsis’ on their pipeline portfolio, some of which are set to enter clinical trials next year. I am thrilled to contribute to its progress through the clinical pipeline.”
With Prof. LoRusso’s insights and leadership, Axcynsis is poised to make significant strides in advancing its innovative Antibody Drug Conjugates and transforming cancer care. Please join us in extending a warm welcome to Prof. LoRusso!
About Axcynsis Therapeutics
Axcynsis Therapeutics is a pioneering biotechnology company based in Singapore, focused on transforming cancer treatment through its innovative Antibody Drug Conjugates (ADCs). Leveraging cutting-edge proprietary technologies, Axcynsis is developing a robust pipeline of next-generation ADC candidates aimed at addressing unmet medical needs. Our goal is to provide more effective and targeted cancer therapies, offering new hope to patients worldwide. With a commitment to revolutionizing oncology care, we are actively advancing our leading assets toward clinical stages.
For more information, visit Axcynsis Therapeutics.
For all media queries, please contact:
Yun Xuan, Wong
